A texaphyrin–oxaliplatin conjugate that overcomes both pharmacologic and molecular mechanisms of cisplatin resistance in cancer cells

Jonathan F. Arambula, Jonathan L. Sessler, Zahid H. Siddik
  • MedChemComm, January 2012, Royal Society of Chemistry
  • DOI: 10.1039/c2md20206a
The author haven't yet claimed this publicationThe author haven't yet claimed this publication

In partnership with: